An Efficacy and Safety Study of Ravulizumab in ALS Participants
Study Identifier:
ALXN1210-ALS-308
ClinicalTrials.gov Identifier:
EudraCT Identifier:
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Other
Study Details
Medical Condition
- Metabolism & Nutrition - Other
- Unmapped
Study Drug
- Drug: Placebo
- Biological: Ravulizumab
Date
Mar 2020 - Oct 2021
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years
Requirements Information
Sex
Female & Male
Age
18+ years
Study Details
Medical Condition
- Metabolism & Nutrition - Other
- Unmapped
Study Drug
- Drug: Placebo
- Biological: Ravulizumab
Date
Mar 2020 - Oct 2021
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years years
Requirements Information
Protocol Summary
The purpose of the study is to assess the efficacy and safety of ravulizumab for the treatment of adult participants with ALS.
Trial Locations
Location
Status
Location
Barrow Neurological Institute
Phoenix, Arizona, United States, 85013
Status
N/A
Location
Neuromuscular Research Center and Clinic
Phoenix, Arizona, United States, 85028
Status
N/A
Location
HonorHealth Research Institute
Scottsdale, Arizona, United States, 85251
Status
N/A
Location
Loma Linda University Medical Center
Loma Linda, California, United States, 92354
Status
N/A
Location
University of Southern California
Los Angeles, California, United States, 90033
Status
N/A
Location
University of California-Irvine
Orange, California, United States, 92868
Status
N/A